National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Midostaurin (Rydapt®) is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).

NCPE Assessment Process Ongoing
Rapid review commissioned 13/08/2018
Rapid review completed 10/09/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.